The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice.
about
Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain functionPotential neuroprotective properties of epigallocatechin-3-gallate (EGCG)Novel epigallocatechin-3-gallate (EGCG) derivative as a new therapeutic strategy for reducing neuropathic pain after chronic constriction nerve injury in miceComplementary and alternative medicine for the treatment of multiple sclerosisR+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.One universal common endpoint in mouse models of amyotrophic lateral sclerosis.The protective effect of growth hormone on Cu/Zn superoxide dismutase-mutant motor neuronsStuck at the bench: Potential natural neuroprotective compounds for concussion.Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical applicationCharacterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis.Quercitrin and quercetin 3-β-d-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant.Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Nutrition and dietary supplements in motor neuron disease.SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegenerationNeuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties.Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model.Nutraceutical antioxidants as novel neuroprotective agents.A review of experimental research on herbal compounds in amyotrophic lateral sclerosis.Natural polyphenols and spinal cord injuryThe discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases.Flavonoid-based therapies in the early management of neurodegenerative diseases.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Green tea polyphenols attenuate glial swelling and mitochondrial dysfunction following oxygen-glucose deprivation in cultures.Anti-inflammatory effect of the epigallocatechin gallate following spinal cord trauma in rat.Implications of white matter damage in amyotrophic lateral sclerosis (Review).Epigallocatechin-3-gallate protects motor neurons and regulates glutamate level.Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation.Effects of a new nutraceutical combination on cognitive function in hypertensive patients.
P2860
Q24617577-448973D5-59FD-4B84-88D8-91C8EB6CABD7Q26748605-05102CB7-A1CA-4EE5-B609-362B6A4AB630Q28546011-F42B8E8E-457B-45B0-B257-36895583F3CDQ29031018-E43E2137-FA27-4CC8-BC15-4CF5345C16C8Q30445597-C27B8CE8-E9C2-4BA5-97F8-FA7A97912FBAQ33936763-8C86CBA2-8872-46BB-92C8-6B118DF40BD3Q35078519-FF0E211A-F9E5-4189-B283-467FA5A47623Q35493114-DF47A7BA-6450-4527-B8B7-EA5D2F46D65EQ36117618-D09CDF4D-B8E3-46D2-9347-C28F4209D20AQ36299228-D1769503-8A1D-482E-9F30-151825162119Q36364363-97143018-A99C-472D-B8D0-ADA5F1254812Q36648907-9E933482-FD8C-4C5F-A452-6847393EFA1FQ37073851-2867C341-8E7C-43D9-866D-531531C370C5Q37101247-A598B93D-A6B5-4472-B417-8A16466A388BQ37418049-E22F2C45-CD56-4C9D-A0C2-D79710933507Q37440150-7B0EAB79-FC68-4367-91D9-9706B0ED0AC2Q37808095-05A978F6-F567-4677-BBE2-774D902A4191Q38092021-52EA8FFB-3E68-4801-AB31-892654E8DD92Q38212924-5EF1663D-3A8F-465C-8865-C868E6B95548Q38233270-85C22A8C-A3F6-4ABE-B42F-F4A05051BF36Q38320199-D7A61B71-F056-4D6B-9FDC-DF30438ED39BQ38573829-A4D3BF6B-53AB-4EA2-A5BF-D3FC6489D81EQ39862749-7CD6F67F-8E4B-48CF-81F4-B56595DD549BQ40232713-B0B0FCCD-71F7-4AA1-A9F7-C6B13FF79165Q42658376-48A40DDE-562E-4A96-8B8B-A0E3ACA548B9Q43058247-E9859421-9D9E-46E0-BCE1-D57BF189F003Q48629388-57D8D7FF-2F22-43AF-B802-FB2BAE718F65Q49270498-70F53896-73CB-42C1-A433-7C6FDA0D82C3
P2860
The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The effect of epigallocatechin ...... progression of ALS model mice.
@en
The effect of epigallocatechin ...... progression of ALS model mice.
@nl
type
label
The effect of epigallocatechin ...... progression of ALS model mice.
@en
The effect of epigallocatechin ...... progression of ALS model mice.
@nl
prefLabel
The effect of epigallocatechin ...... progression of ALS model mice.
@en
The effect of epigallocatechin ...... progression of ALS model mice.
@nl
P2093
P1433
P1476
The effect of epigallocatechin ...... progression of ALS model mice.
@en
P2093
Chiwon Song
Hee-Tae Kim
Hyun Young Kim
Ki-Wha Yang
Kwang Woo Lee
Kyu-Yong Lee
Myung Sil Hwang
Myung-Ho Kim
Ok-Hee Kim
P304
P356
10.1016/J.NEULET.2005.10.056
P407
P577
2005-12-13T00:00:00Z